Axsome Therapeutics
AXSM
172.97
-1.37
-0.79%
Axsome Therapeutics
US · AXSM
#1533 by market cap
Listed 2015
172.97
-1.37
-0.79%
Live - 5344 symbols - heartbeat 242s ago
· 2026-10-08 09:15
Pre-market
172.85
-0.07%
After-hours
172.97
0.00%
Overnight
172.59
-0.22%
- Market cap
- 9.06B
- P/E (TTM)i
- -46.13
- P/Bi
- 108.79
- EPSi
- -3.68
- Div yieldi
- 0.00%
- 52W posi
- 38%
Reader sentiment
Are you bullish or bearish on AXSM?
Anonymous reader poll. Unscientific, not investment advice.
About Axsome Therapeutics
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
- Founded
- 2012
- CEO
- Dr. Herriot Tabuteau, M.D.
- Employees
- 925
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- axsome.com
Company profile
- Exchange
- US
- Symbol
- AXSM
- Market-cap rank
- #1533
- Listing date
- 2015-11-19
- Market cap
- 9.06B
- Float cap
- 7.69B
- Shares out
- 52.38M
- Float shares
- 44.46M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 09:15:09 · For reference only, not investment advice and not tailored to your situation.